Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study)

Ophthalmology

Volumn 119, Issue 9, 2012, Pages 1867-1873

  Nguyen, Quan Dong ^a   Schachar, Ronald A ^b   Nduaka, Chudy I ^b   Sperling, Marvin ^b   Klamerus, Karen J ^b   Chi Burris, Katherine ^b   Yan, Eric ^b   Paggiarino, Dario A ^b   Rosenblatt, Irit ^c   Aitchison, Roger ^d   Erlich, Shai S ^d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b PFIZER INC   (United States)

^c RABIN MEDICAL CENTER   (Israel)

^d QBI Enterprises Ltd   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

PF 04523655; RANIBIZUMAB; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN ISCHEMIA; CONJUNCTIVAL HEMORRHAGE; CONTROLLED STUDY; CORNEA EROSION; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; EYE PAIN; FEMALE; HUMAN; INTRAOCULAR PRESSURE; KERATITIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA; RETINA EDEMA; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; TRANSIENT ISCHEMIC ATTACK; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; VITREOUS BODY DETACHMENT;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; DRUG THERAPY, COMBINATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINA; RNA INTERFERENCE; RNA, SMALL INTERFERING; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84865678868     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2012.03.043     Document Type: Article

References (22)

1. Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report 1 Arch Ophthalmol 117 1999 1329 1345
2. J. Folkman, E. Merler, C. Abernathy, G. Williams Isolation of a tumor factor responsible for angiogenesis J Exp Med 133 1971 275 288
3. J. Folkman Tumor angiogenesis: therapeutic implications N Engl J Med 285 1971 1182 1186
4. L.P. Aiello, E.A. Pierce, E.D. Foley Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins Proc Natl Acad Sci U S A 92 1995 10457 10461
5. M.G. Krzystolik, M.A. Afshari, A.P. Adamis Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment Arch Ophthalmol 120 2002 338 346
6. D.W. Leung, G. Cachianes, W.J. Kuang Vascular endothelial growth factor is a secreted angiogenic mitogen Science 246 1989 1306 1309
7. M.J. Tolentino, D.S. McLeod, M. Taomoto Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate Am J Ophthalmol 133 2002 373 385
8. E.S. Gragoudas, A.P. Adamis, E.T. Cunningham Jr VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group Pegaptanib for neovascular age-related macular degeneration N Engl J Med 351 2004 2805 2816
9. P.J. Rosenfeld, R.M. Rich, G.A. Lalwani Ranibizumab: phase III clinical trial results Ophthalmol Clin North Am 19 2006 361 372
10. G.A. Lalwani, P.J. Rosenfeld, A.E. Fung A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study Am J Ophthalmol 148 2009 43 58
11. P. Abraham, H. Yue, L. Wilson Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2 Am J Ophthalmol 150 2010 315 324
12. M. Lee, M. Bikram, S. Oh Sp1 dependent regulation of the RTP801 promoter and its application to hypoxia inducible VEGF plasmid for ischemic disease Pharm Res 21 2004 736 741
13. C.J. Sabers, M.M. Martin, G.J. Brunn Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells J Biol Chem 270 1995 815 822
14. M.N. Corradetti, K. Inoki, K.L. Guan The stress-inducted proteins RTP801 and RTP801L are negative regulators of the mammalian target of rapamycin pathway J Biol Chem 280 2005 9769 9772
15. F.J. Dumont, Q. Su Mechanism of action of the immunosuppressant rapamycin Life Sci 58 1996 373 395
16. A. Brafman, I. Mett, M. Shafi Inhibition of oxygen-induced retinopathy in RTP801-deficient mice Invest Ophthalmol Vis Sci 45 2004 3796 3805
17. M. Robbins, A. Judge, I. MacLachlan siRNA and innate immunity Oligonucleotides 19 2009 89 101
18. T. Kawai, S. Akira Toll-like receptor and RIG-I-like receptor signaling Ann N Y Acad Sci 1143 2008 1 20
19. S. Shiose, Y. Chen, K. Okano Toll-like receptor 3 is required for development of retinopathy caused by impaired all-trans-retinal clearance in mice J Biol Chem 286 2011 15543 15555
20. M.E. Kleinman, K. Yamada, A. Takeda Sequence- and target-independent angiogenesis suppression by siRNA via TLR3 Nature 452 2008 591 597
21. M.E. Kleinman, H. Kaneko, W.G. Cho Short-interfering RNAs induce retinal degeneration via TLR3 and IRF3 Mol Ther 20 2012 101 108
22. K. Karikó, M. Buckstein, H. Ni, D. Weissman Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA Immunity 23 2005 165 175